Emcure Pharmaceuticals Ltd Q1 FY27 Results Analysis: Revenue Surges 23%, Gross Margin Compresses 340 bps
Emcure Pharmaceuticals Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 2,580.45 Cr (+22.85% YoY) and PAT growth of +42.05% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 06, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 2,580.45 Cr (+22.85% YoY) |
| PAT (Q1) | Rs. 292.49 Cr (+42.05% YoY) |
| EBITDA margin | 19.69% (+50 bps YoY) |
| EPS (Q1) | Rs. 15.50 (+41.94% YoY) |
| Market cap | Rs. 36,735.35 Cr |
| CMP | Rs. 1,936.70 |
Quarter Snapshot
EMCURE delivered a strong Q1 with revenue growth of 22.85% YoY, nearly double its guided low-to-mid teens range, driven by a 34.2% surge in international business. Operating leverage was evident as employee costs grew only 4.1%. However, gross margin compressed 340 bps due to input cost inflation and mix shift, and domestic growth lagged the market.
Key Investment Insights
Key Positives
- Revenue grew 22.85% YoY to Rs.2,580.45 Cr, nearly double the guided low-to-mid teens range
- PAT attributable to owners grew 42.05% YoY to Rs.293.98 Cr
- International revenue grew 34.2% YoY, with all three regions (RoW, Europe, Canada) posting >24% growth
- EBITDA margin expanded 50 bps YoY to 19.7%
- Employee costs grew only 4.1% YoY, demonstrating operating leverage
- Adjusted PAT grew 33.8% YoY, confirming clean operating momentum
Risk Factors
- Domestic revenue grew 10.2% YoY, below IPM growth of ~12% and below management's aspiration of industry +100-200 bps
- Gross margin compressed 340 bps YoY to 58.4% due to input cost inflation (solvents +30%) and mix shift toward lower-margin international markets
- Freight cost headwinds flagged in pre-call note, though other expenses grew below revenue
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.